|
| |
|
 |
| |
A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care
by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety
of cancers.
Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many
advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of
product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its
blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various
stages of clinical development.
Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development
by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development
targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its
research programs into clinical development over the coming years.
ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of
biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with
one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development
and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.
|
|
